Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

BACKGROUND: The once-daily oral combination of daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is effective and well tolerated in patients with hepatitis C virus (HCV). However, further field-practice studies are necessary to investigate the effectiveness and safety of the D...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Drugs Context
Main Authors: Sacco, Rodolfo, Messina, Vincenzo, Gentilucci, Umberto Vespasiani, Adinolfi, Luigi Elio, Ascione, Antonio, Barbarini, Giorgio, Barlattani, Angelo, Cariti, Giuseppe, Cozzolongo, Raffaele, Fimiani, Basilio, Francavilla, Ruggiero, Furlan, Caterina, Garrucciu, Giovanni, Iovinella, Vincenzo, Rinaldi, Luca, Marignani, Massimo, Begini, Paola, Palitti, Valeria Pace, Pellicelli, Adriano M, Scifo, Gaetano, Facciorusso, Antonio, Giacomelli, Luca, Shah, Aashni, Bertino, Gaetano, Perazzo, Serena, Bresci, Giampaolo, Izzi, Antonio
Formato: Artigo
Idioma:Inglês
Publicado em: BioExcel Publishing Ltd 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7747789/
https://ncbi.nlm.nih.gov/pubmed/33408749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2020-4-11
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados